CClinicalTrials.gg
WithdrawnNCT04872452Updated Nov 13, 2023

Analysis of Cutaneous Nerve Biopsies in Gastrointestinal Motility Disorders

An interventional study of Skin biopsy in Small Fiber Neuropathy and Gastrointestinal Dysmotility, sponsored by Johns Hopkins University. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-13.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Other

Why this study was withdrawn
Investigators departed institution prior to any recruitment
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is being done to evaluate cutaneous nerve biopsies from patients with refractory gastrointestinal motility disorders. The purpose of the study is to evaluate skin biopsies for signs of small fiber neuropathy in GI dysmotility patients, which may provide a better understanding of the underlying pathology of their condition. Specifically, identifying any small fiber neuropathy that may exist in the peripheral nervous system may help us to better understand the mechanism of presumed enteric neuropathy that may be involved in causing GI dysmotility.

Read the detailed description
  1. Gather basic, clinical information and perform small 3-6mm skin biopsies.
  2. Identify characteristics of epidermal nerve fibers in patients with symptoms of gastrointestinal dysmotility
  3. To isolate skin-derived precursor cells from skin biopsies and test their ability to generate neurons in vitro and in immune-deficient mouse models.
02

Conditions studied

  • Small Fiber Neuropathy
  • Gastrointestinal Dysmotility

Browse trials for

03

In context

Small Fiber Neuropathy

47 studies on the registry are indexed under Small Fiber Neuropathy; 12 are open to participants now.

Browse Small Fiber Neuropathy studies →

Lead sponsor

Johns Hopkins University is the lead sponsor of 1,783 studies on the registry; 313 are open to participants now.

Of its 203 completed or terminated interventional studies of FDA-regulated products, 140 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Individual with a gastrointestinal motility disorder that has failed both clinical and surgical options for symptomatic management

Exclusion criteria

Exclusion Criteria:

  • Child 17 years of age or younger
  • Individuals incapable of informed consent
  • Patient with diseased skin or on drugs which affect skin biology.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Gastrointestinal dysmotility participants

    Procedure: Skin biopsy

  • Other
    Healthy participants

    Procedure: Skin biopsy

Interventions

  • ProcedureSkin biopsy

    Any combination of the following six 3-6mm skin biopsies may be taken: palm, dorsum of hand, calf, other non-genital and non-face (this last one includes areas for use as negative controls which are not on the distal limbs). No more than 6 biopsies will be taken at one time.The biopsy size 3-6mm and method (punch, shave or wedge) will be done depending on the biologic assay destined for the biopsy. While 3mm will be sufficient for microarray analysis, 6mm will be required for any cell sorting preceding microarray analysis.

06

What researchers measure

Primary outcomes

  1. Presence of small fiber neuropathy in skin biopsy samples

    Presence or absence of small fiber neuropathy obtained after the skin biopsy procedure.

    Time frame: Only one biopsy but analysis may take one year.

07

Study locations

1 site
  • Johns Hopkins Bayview Medical Center
    Baltimore, Maryland 21224, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04872452
Lead sponsor
Johns Hopkins University
Responsible party
Sponsor
First posted
May 4, 2021
Start date
Dec 22, 2023 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Jan 31, 2026 (estimated)
Last update
Nov 13, 2023

Study contacts

Pankaj J Pasricha, MD
principal investigator · Johns Hopkins University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion